Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XOMA Royalty Corporation filings document a biotechnology royalty aggregator with Nasdaq-listed common stock, Series A cumulative perpetual preferred stock, and Series B depositary shares. Form 8-K reports cover operating results, Regulation FD presentations, material definitive agreements, completed acquisition activity, and officer appointments tied to the company’s royalty aggregation strategy.
Proxy materials describe annual meeting procedures, board and stockholder voting matters, and governance disclosures. The filing record also documents the company’s capital structure, including preferred stock classes, and formal disclosures around completed acquisitions and related legacy asset information.
WYSZOMIERSKI JACK L reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Jack L. Wyszomierski received an equity grant in the form of restricted stock units. He was awarded 3,586 RSUs, each representing one share of common stock at settlement. Following the grant, he directly holds 25,116 shares of common stock.
The 3,586 RSUs vest in equal monthly installments over 12 months from the grant date, conditioned on his continued service with the company. This compensation-related award is not an open-market purchase or sale but a stock-based incentive.
LIMBER JOSEPH M reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Joseph M. Limber received a grant of 3,586 restricted stock units (RSUs) of common stock at no purchase price. Each RSU represents one share of common stock and will vest in equal monthly installments over 12 months from the grant date, subject to his continued service.
Following the grant, Limber directly holds 12,820 shares of common stock. He also reports direct holdings of 10,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock and 20,000 Depositary Shares representing 8.375% Series B Cumulative stock.
XOMA Royalty Corp director Natasha Hernday received an equity grant of 3,586 restricted stock units (RSUs) of common stock. The grant has a stated price of $0.00 per share and is described as a compensation-related award rather than an open-market purchase.
Each RSU converts into one share of XOMA common stock upon settlement and will vest in equal monthly installments over 12 months from the grant date, contingent on Hernday’s continued service. Following this grant, she directly holds 12,592 shares of common stock and 4,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock.
XOMA Royalty Corp director Matthew D. Perry received a grant of 3,586 restricted stock units (RSUs) of common stock at no cost. Each RSU converts into one share and will vest in equal monthly installments over 12 months, contingent on his continued service. Following this equity award, he directly owns 27,426 shares of XOMA common stock.
Franklin Heather L reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Heather L. Franklin received a grant of 3,586 restricted stock units (RSUs) of common stock on May 21, 2026. The award was made at no cash cost per share as part of equity compensation. Each RSU represents the right to receive one share of XOMA common stock at settlement and will vest in equal monthly installments over 12 months, subject to her continued service with the company. Following this grant, Franklin directly owns 9,557 shares of common stock, reflecting a modest, routine increase in her equity stake through compensation rather than open‑market buying.
Kosacz Barbara reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Barbara Kosacz received a grant of 3,586 restricted stock units (RSUs) of common stock. The RSUs were awarded at no cash cost per unit and will vest in equal monthly installments over 12 months, conditioned on her continued service to the company. Following this equity award, she holds 9,557 shares of common stock directly.
XOMA Royalty Corporation filed a preliminary proxy statement/prospectus as part of a Form S-4 registration to implement a Holding Company Reorganization and a proposed merger with Ligand Pharmaceuticals' Merger Sub. Under the Merger Agreement, each XOMA Royalty share will convert into $39.00 cash plus one non-transferable contingent value right (CVR).
The CVR entitles holders to contingent cash payments, if any, derived from net proceeds of pending litigation against Janssen; CVRs may have no value. The Merger and Holding Company Reorganization require stockholder approval and customary regulatory and closing conditions. The proxy describes treatment of preferred stock, equity awards and warrants, dissenter’s rights under Nevada law, and material risks including uncertainty around CVR timing and value.
XOMA Royalty Corporation reported the results of its 2026 Annual Meeting of Stockholders. Shareholders approved an amendment and restatement of the 2010 Long Term Incentive and Stock Award Plan, adding 425,000 shares of common stock for equity awards and extending the plan’s term to March 16, 2036.
They also approved the 2026 Employee Stock Purchase Plan, making 500,000 shares available for employee purchases, and ratified Deloitte & Touche LLP as independent auditor. All director nominees were elected and the advisory vote on executive compensation passed. As part of a previously announced merger process, the board adopted bylaw amendments addressing Nevada controlling interest statutes and adding exclusive forum provisions.
XOMA Royalty Corp large shareholders affiliated with Biotechnology Value Fund converted Series X Convertible Preferred Stock into common stock. On May 14, 2026, entities in the reporting group converted a total of 5,003 shares of Series X Preferred into 5,003,000 shares of common stock at a $4.03 per share conversion price. After these conversions, the Form 4 shows only common stock positions, with the Series X Preferred balances reduced to zero for the reporting entities involved. The transactions are reported as exempt from short-swing profit rules under Rule 16b-6(b) and reflect changes in the form of ownership rather than open-market buying or selling.
BVF Partners and affiliated funds report a 43.3% stake in XOMA Royalty Corp following conversion of preferred shares. The group now beneficially owns 7,593,303 common shares, calculated using 12,541,030 shares outstanding as of May 7, 2026 plus 5,003,000 shares received in a "Series X Conversion."
On May 14, 2026 the reporting persons increased the Series X Beneficial Ownership Limitation to 45% and converted all their Series X Preferred Stock into common shares at a conversion price of $4.03 per share. BVF, BVF2, Trading Fund OS and managed accounts together invested roughly $44.1 million in the converted and other purchased shares.